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Abstract 
Background: The cytotoxic effect of chemotherapeutic agents to the oral mucosa, as a side-
effect of cancer treatment, is a major problem. Cooling the oral mucosa using ice chips in 
conjunction with chemotherapy is known to reduce the severity of oral mucositis. However, 
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although the use of ice chips is of clinical value, this method of cooling has inherent 
problems including discomfort for the patient, non-uniformity and fluctuations in cooling 
temperature throughout the oral cavity. Furthermore, despite being used clinically, it is not 
known what reduction in temperature is required to prevent oral mucositis. The aim of the 
present study was therefore to determine in vitro if the cytotoxic effect of 5-Fluorouracil (5-
FU) on the oral mucosa could be reduced by lowering the temperature during 
chemotherapeutic treatment.  
Methods: Tissue engineered oral mucosal (TEOM) models were incubated at 20, 25, 30, or 
35 °C for 30 minutes followed by exposure to a clinically relevant concentration of 5-FU 
 ȝJPO for two hours and compared to untreated models (35°C). Cell viability and 
inflammatory cytokine production (IL-6 and TNF-ĮZHUHPHDVXUHGXVLQJ3UHVWR%OXHDQG
ELISA, respectively.  
Results: TEOM models incubated at 20°C showed an increased cell viability and had a 
reduced IL-6 and TNF-Į SURGXFWLRQ compared to models treated with 5-FU incubated at 
35°C.  
Conclusion: This study demonstrates a reduced cytotoxic effect to the TEOM by reducing the 
temperature of the tissue during chemotherapy treatment and suggests that decreasing the 
temperature to 20°C could have clinical advantages. 
 
Introduction 
Chemotherapy, along with radiotherapy and surgery are the most commonly used strategies to treat 
cancer (1). The main action of chemotherapy is to target rapidly dividing cells, which is a 
characteristic feature of cancer cells (2). However, oral epithelial cells are also highly proliferative (3) 
and are therefore susceptible to the cytotoxic effect of chemotherapeutic agents (4). 5-Fluorouracil (5-
FU) is a well-established chemotherapeutic drug and has for a long time been used for the 
management of a range of different cancers including colorectal, breast and skin cancer, but is also an 
alternative treatment in patients with metastatic or recurrent head and neck cancer. 5-FU is an 
analogue of uracil and enters the cells through the same facilitated transport mechanism as the 
nucleotide. Intracellularly, 5-FU is converted to several active metabolites that are further 
incorporated into macromolecules such as DNA and RNA, inhibiting their normal functions (5-7). 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The mechanism by which chemo- and radiation therapy induce cell damage is believed to arise from 
of a cascade of biological events taking place in the underlying subepithelium. Subsequent activation 
of transcription factors and release of several pro-inflammatory cytokines, including IL-6 and TNF-Į
in turn leads to a compromised mucosal lining and ulcerations known as mucositis (8).   
 
Mucositis is common debilitating side effect following chemotherapy and is frequently seen in 
clinical settings prior to hematopoietic stem cell transplantation (9). It affects the lining epithelium of 
the entire oral and gastrointestinal tract (10) and in its mildest form manifests clinically as an 
erythematous lesion. However, in more severe forms, painful ulceration caused by epithelial 
detachment from the underlying submucosa is observed and routinely necessitates narcotic analgesia 
(11). Mucositis may also interfere with food and liquid intake and have a negative impact on several 
aspects of quality of life (emotional, social and functional) (12, 13).   
 
Chewing on ice chips before and during chemotherapy infusion is currently the standard approach for 
prevention of oral mucositis (14). However, ice chips are extremely cold upon first exposure in the 
oral cavity causing discomfort including headache and teeth sensations (15). In addition, the intra-oral 
temperature during ice chip treatment is not constantly maintained and declines rapidly, therefore 
providing only transient benefit to the patient. The aim of this study was to determine if cooling, using 
a constant low temperature, caused a reduction in the pro-inflammatory cytokines release and 
cytotoxic effect of 5-FU treatment on tissue engineered oral mucosa (TEOM) and therefore prevent 
tissue damage.  
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Material and methods 
 
Cell culture 
Normal oral keratinocytes (NOK) and normal oral fibroblasts (NOF) were isolated and 
cultured from oral mucosal biopsies obtained from patients with written, informed consent 
with ethical approval (Sheffield Research Ethics Committee 09/H1308/66) as previously 
described (16) and in accordance with the World Medical Association Declaration of 
Helsinki.  NOK were cultured in flavin- and adenine-HQULFKHG PHGLXP *UHHQ¶V PHGLXP
FRQVLVWLQJRI'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP'0(0DQG+DP¶V)PHGLXPLQD
3:1 (v/v) ratio supplementeGZLWKYYIRHWDOFDOIVHUXP)&6ȝ0FKROHUDWR[LQ
 QJPO HSLGHUPDO JURZWK IDFWRU  ȝJPO K\GURFRUWLVRQH  P0 DGHQLQH  ȝJPO
LQVXOLQ  ȝJ PO WUDQVIHUULQ  P0 JOXWDPLQH  ȝ0 WULLRGRWK\URQLQH  ȝJPO
amphotericin B, 100 IU/mO SHQLFLOOLQ DQG  ȝJPO VWUHSWRP\FLQ 12) ZHUH FXOWXUHG LQ
'0(0VXSSOHPHQWHGZLWK)&6P0JOXWDPLQH,8POSHQLFLOOLQDQGȝJPO
streptomycin.  
 
Production of TEOM models  
TEOM models were produced as previously described (16). Briefly, de-epithelized dermis (1 cm2) 
was placed in each well of a 6-well plates, an 8 mm diameter steel ring laid on the upper surface and 
5x105 NOF and 1x106 NOK added in 500 µORI*UHHQ¶VPHGLXP0HGLXPZDVFKDQJHGWZLFHGDLO\
for 48 h at which point the rings were removed and the models incubated at an air-to-liquid interface 
on steel grids for a further 10 days at 37 °C, 5% CO2. 
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Drug treatments 
To determine the optimum drug concentration, TEOM were treated with 2 ml of 5-FU, dissolved in 
*UHHQ¶V PHGLD DW WKUHH different clinically relevant concentrations (54, 162 and 324 µg/ml) along 
with a control (no drug applied) and SDS-treated (1%) control for 2 h. Following the incubation, 
TEOM models were rinsed in pre-warmed PBS to eliminate superficial cytostatics and replaced with 
pre-warmed (37 °C) medium. Models were incubated for a further 30 min at 37 °C, washed again 
with pre-warmed PBS to eliminate profound cytostatics, replaced with fresh medium and incubated 
for 48 h at 37 °C before analysis. 
 
Temperature effects on TEOM  
Based on initial experiments it was determined that a 5-FU concentration of 162 µg/ml would enable 
the effects of temperature to be assessed in the TEOM models. TEOM models were pre-incubated at 
20, 25, 30, or 35 °C for 30 minutes before treatment with 5-)8ȝJPO for 2 h or at 35 °C with 
no drug used as a control. Following the incubation, TEOM models were rinsed in 37 °C pre-warmed 
PBS to eliminate superficial cytostatics and replaced with pre-warmed medium. Models were 
incubated for a further 30 minutes at 37 °C, washed again with pre-warmed PBS to eliminate 
profound cytostatics, replaced with fresh medium and incubated for 48 h at 37 °C before analysis. 
 
Cell viability assay  
To measure cell viability, PrestoBlue® (ThermoFisher, Massachusetts, United States) was used 
according to the PDQXIDFWXUHU¶V instructions. Briefly, TEOM models were immersed in 1.1 ml of 
PrestoBlue® reagent diluted 1:40 in DMEM + 10% FCS (v,v) and incubated in the dark for 2 h at 37 
°C LQ&2ȝORIPHGLD was transferred to a 96-well plate in duplicate and measured using a 
spectrophotometer (Tecan, Männedorf, Switzerland) at excitation 560 nm and emission 590 nm. 
Optical density values were normalised relative to the control (0 µg/ml 5-FU), which was set at 1. 
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Enzyme-linked immunosorbent assay 
&RPPHUFLDOO\DYDLODEOH(/,6$2SW(,$%'%LRVFLHQFHNLWVZHUHXVHGDFFRUGLQJWRWKH
PDQXIDFWXUHU¶V LQVWUXFWLRQV WR PHDVXUH OHYHOV RI ,/-6 and TNF-Į in TEOM conditioned 
medium as described previously (17).  
 
Histological analysis 
For histological analysis, TEOM were removed from the culture medium, washed with PBS 
and fixed in 10% buffered formalin overnight. The model was bisected and subjected to 
URXWLQHKLVWRORJLFDOSURFHVVLQJDQGWKHQSDUDIILQZD[HPEHGGHG)LYHȝPVHFWLRQVZHUHFXW
using a Leica RM2235 microtome (Leica microsystems) and stained with haematoxylin and 
eosin (H&E). 
 
Statistics 
Data are presented as mean ± standard deviation (SD) of three independent experiments (n=3) with 
each test performed in triplicate unless otherwise stated. ANOVA (One-Way ANOVA and 'XQQHWW¶V
multiple hypothesis correction) multiple statistical comparisons were performed using GraphPad 
Prism v6.00 (GraphPad Software, La Jolla, CA, USA) and differences between test and control 
groups considered significant when p < 0.05. 
 
Results 
An initial drug dose-response was performed to determine the optimum concentration of 5-FU needed 
to reduce cell viability in full-thickness TEOM to subsequently enable the investigation of a cooling 
effect during drug treatment on cell viability and cytokine release. Cell viability was measured after a 
48 h incubation following a 2 h treatment with 54, 162 or 324 µg/ml 5-FU. A dose-response effect 
was observed with 5-FU at a concentration of 54 µg/ml having no effect on TEOM model viability 
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but the higher concentrations (162 and 324 µg/ml) causing a statistically significant decrease in 
viability with an overall reduction of 36% (p<0.001) and 28% (p<0.05), respectively (Figure 1A). 
Following the same trend, an increase in TNF-Į SURGXFWLRQ was observed for the higher 
concentrations of 5-FU (162 or 324 µg/ml) tested following a 2 h incubation, although these did not 
reach significance from the untreated control (Figure 1B). Based on these results a drug concentration 
of 162 µg/ml was used for all further experiments. 
 
To investigate the effect of cooling on cell viability, TEOM models were treated with 5-FU (162 
µg/ml) for 2 h at 20, 25, 30 or 35°C and compared to untreated (media alone) controls at 35°C. A 
statistically significant decrease in viability for all 5-FU treated TEOM models at all of the 
temperature conditions tested compared to untreated controls was observed in a temperature-
dependent manner, suggesting that lower temperatures increase cell viability and reduce the effects of 
5-FU treatment (Figure 2). Although there was a trend of increased viability at lower temperatures 
with 5-FU treatment, these did not reach statistical significance when TEOM incubated at different 
temperatures were compared to each other.  
Interestingly, 5-FU-treated TEOM displayed increased secretion of the pro-inflammatory cytokines 
IL-6 and TNF-ĮDW DOO WHPSHUDWXUHV WHVWHGFRPSDUHG WRXQWUHDWHG FRQWUROV ,/-6 secretion increased 
markedly when cells were incubated witK  ȝJPO -FU at 35°C and 30°C compared to cells 
incubated with medium alone at 35°C, although this was not statistically significant (Figure 3). Levels 
of TNF-ĮZHUHVLJQLILFDQWO\JUHDWHUSin models WUHDWHGZLWKȝJPO-FU and incubated at 
35°C compared with medium alone untreated mucosal models incubated at 35°C. (Figure 4). 
Moreover, levels of TNF-Į ZHUH VLJQLILFDQWO\ ORZHU S LQ mucosal models treated with 162 
ȝJPO-FU at 20°C compared with TEOM treated with the same concentration of 5-FU but incubated 
at the higher temperature of 35°C (Figure 4). These data suggest that incubating 5-FU-treated TEOM 
models at 20°C reduces the pro-inflammatory cytokine burden whilst increasing tissue viability 
compared to those incubated at 35°C.   
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Histological examination of the TEOM for each condition tested demonstrates that the structural 
integrity of the TEOM models are maintained 48 h post-incubation with 5-FU (Figure 5). 
 
Discussion 
Oral mucositis affects approximately 80% of all cancer patients treated with high doses of 
chemotherapy prior to stem cell transplantation (18). Cooling the oral mucosa using ice chips has 
been demonstrated to reduce the risk and severity of oral mucositis (19, 20). The presumed protective 
mechanism of reducing the temperature of the oral mucosa is believed to be a local vasoconstriction 
resulting in a reduced drug delivery to the epithelial cells as well as lowered metabolic activity in the 
basal layer, making the epithelium less susceptible to cytotoxic agents (19).  
 
The TEOM is a composite model of oral epithelial cells and oral fibroblasts cultured on a 
decellualarised dermal scaffold and enables in vitro investigations in a relevant physiological 
environment (21). Although being the best in vitro model for the purpose of this study, it does not 
completely replicate the complex structure of the oral mucosa seen in vivo (8). In particular the model 
lacks immune cells and blood vessels, which prevents the possibility of studying the importance of 
vasoconstriction. Based on these limitations our findings are most likely attributed to lowered 
metabolic activity to explain the prevention of irreversible cell damage after exposure to 
chemotherapeutic agents. Furthermore, considering the absence of essential immune components the 
models used in this particular experiment may not reflect the immune response in its entirety that is 
observed in vivo.  
Pre-incubation temperatures for the TEOM models were selected based on two separate studies on 
healthy volunteers where an approximate mean temperature of 25-30 °C was obtained in the oral 
mucosa (22, 23). These temperatures were further selected with an interval of 5 °C since they 
represented clinically relevant temperatures.  
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The decision to use 5-FU was based on the fact that it is one of the most commonly used 
chemotherapeutic drugs in clinical oncologic practice (7). 5-FU has several known adverse effects 
such as gastro-intestinal and oral mucositis, which is a major complication (24). Furthermore, it has 
been demonstrated that 5-FU induces an inflammatory response, including the production of the pro-
inflammatory cytokines IL-6 and TNF-Į in animal models (25), cytokines that were investigated in 
this in vitro study.  
 
Mucositis is described as a complex biological process that occurs as a result of a series of 
interactions, including the activation of the transcription factor nuclear factor-kappa B (NF-ț%DQG
release of pro-inflammatory cytokines e.g. IL-6 and TNF-Į (8). Previous studies have shown an 
increase in expression of such factors in experimental models of anti-cancer treatment (21, 26, 27). In 
accordance with the findings of these previous studies, we found that TEOM models exposed to 5-FU 
expressed pro-inflammatory cytokines to a greater extent than untreated controls. In our previous 
study we did not detect expression of TNF-ĮLQDQin vitro model of radiation-induced mucositis (21), 
whereas levels of TNF-ĮZHre increased significantly by 5-FU treatment in this study. This disparity 
suggests subtle differences in the cytokines released by chemo- as opposed to radiotherapy induced 
oral mucositis.  Monocytes and macrophages are thought to be the main sources of cytokine (e.g. IL-6 
and TNF-Į production in vivo. Although, these cytokines are also produced by activated 
lymphocytes, endothelial/epithelial cells, and fibroblasts (28), the latter being the source of immune 
response in our models. Since our mucosal model does not contain an immune component it is likely 
that pro-inflammatory cytokine release is increased further in vivo upon chemotherapy treatment, 
where immune cells are present. 
This study demonstrated that TEOM models incubated with 5-FU at lower temperatures had an 
improved ability to preserve their cell viability compared to models incubated at higher temperatures. 
The reverse temperature dependent pattern was seen for IL-6 production and the pattern was even 
more obvious for TNF-Į H[SUession, as treated models incubated at lower temperatures had 
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significantly lower production of pro-inflammatory cytokines. This was particularly true in models 
incubated at 20 °C compared to those incubated at 35 °C. These results are consistent with previous 
clinical reports showing that cooling has a protective effect on mucosa exposed to chemotherapeutic 
agents (19, 20).  
 
In contrast to the extensive epithelial damage caused in radiated TEOM-models, the histological 
examination of TEOM-models exposed to 5-FU showed an intact structural integrity at 48 h post 
incubation. The preservation of the epithelium is considered positive as clinical ulcerations are 
characterized by a loss of epithelium leaving an exposure of the underlying connective tissue (29). It 
is difficult to state if a correlation exists between preservation of the integrity of epithelial and 
incubation at lower temperatures in TEOM-models exposed to 5-FU since models were followed only 
for 48 h. However, based on our histological examination no such correlation exists. Further studies 
with longer follow-up periods are needed to investigate if a true correlation exists. Furthermore, it 
would be of interest to study WKHPRGHO¶VELRORJLFDOPHFKDQLVP and its cellular response to 5-FU as 
well as other chemotherapeutic agents when blood vessels and immune components are incorporated 
in the model. Partly because these are key components in the pathobiology of the immune system but 
in particular to further mimic the physiology of the oral mucosa seen in vivo.  
 
An example of other chemotherapeutic agents that could have been used and evaluated in this study is 
Melphalan, a bifunctional alkylating agent that does not require metabolic activation. Similar to 5-FU, 
it incorporates into macromolecules but instead Melphalan exerts its effects through DNA inter-strand 
cross-linking, which leads to replication arrest and cell death (30). 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In summary, this is the first study to evaluate the cytotoxic effect of a chemotherapeutic agent 
on oral mucosa in vitro and also the first in vitro study to investigate if the cytotoxic effect 
could be reduced by lowering the temperature. Our findings show that models incubated at 
lower temperatures have a higher cell viability and reduced cytokine production and further 
suggest that decreasing oral mucosal temperature to 20 °C in conjunction with chemotherapy 
could have clinical advantages.  
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Figure legends: 
Figure 1: Dose-response effects of 5-FU on tissue-engineered oral mucosa models. Tissue-
engineered oral mucosa model viability (A) and TNF-ĮSURGXFWLRQ%IROORZLQJLQFXEDWLRQZLWK
increasing 5-FU concentrations (54, 162 and 324 µg/ml) after a 2 hours incubation period compared 
to untreated controls. Data are presented as mean ± standard deviation (n=3), ***<0.001 and *p<0.05. 
  
Figure 2: The effects of cooling on tissue-engineered oral mucosa model viability. Tissue-
engineered oral mucosa model viability was measured 48 hours post incubation following treatment 
with 5-)8ȝJPOIRUWZRKRXUVDWGLIIHUHQWFRROLQJWHPSHUDWXUHVDQG&
FRPSDUHGWRXQWUHDWHGFRQWUROV&'DWDDUHSUHVHQWHGDVPHDQVWDQGDUGGHYLDWLRQQ S
SS 
  
Figure 3: The effects of cooling on tissue-engineered oral mucosa model IL-6 secretion. Tissue-
engineered oral mucosa model IL-6 secretion was measured 48 hours post incubation following 
treatment with 5-)8ȝJPOIRUWZRKRXUVDWGLIIHUHQWFRROLQJWHPSHUDWXUHV(20, 25, 30 and 
35°C) compared to untreated controls (35°C). Data are presented as mean ± standard deviation (n=3).  
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 Figure 4: The effects of cooling on tissue-engineered oral mucosa model TNF-Į production. 
Tissue-engineered oral mucosa model TNF-Įproduction was measured 48 hours post incubation 
following treatment with 5-)8ȝJPOIRUWZRKRXUVDWGLIIHUHQWFRROLQJWHPSHUDWXUHV
and 35°C) compared to untreated controls (35°C). Data are presented as mean ± standard deviation 
(n=3), * SS  
 
Figure 5. Histological examination of tissue-engineered oral mucosa models post-treatment with 
cooling. Structural integrity of tissue-engineered oral mucosa models following 5-FU treatment (162 
µg/ml) at specified temperatures (20, 25, 30 and 35°C) compared to untreated controls (35°C). Scale 
bar=100 µm. 
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